Magnetic Nanoparticles Leap From Lab Bench to Breast Cancer Clinical Trials

May 2, 2018

Click here to view the printer friendly version of this press release

Manhattan Scientifics, Inc. today issued an update on its affiliates' progress regarding its Early Cancer Detection Diagnostic

The entire article can be read at this link:

Manhattan Scientifics seed funded Imagion Biosystems. MHTX invested eight years of development and owns 64 million shares of Imagion Biosystems after its public offering on the Australian stock exchange. (IBX.ASX)

About Manhattan Scientifics

Manhattan Scientifics Inc. ( is focused on commercialization of disruptive technologies in the nano medicine space.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.